Willingham M - Search Results

1

Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer.

Hassan R, Remaley AT, Sampson ML, Zhang J, Cox DD, Pingpank J, Alexander R, Willingham M, Pastan I, Onda M. Hassan R, et al. Among authors: willingham m. Clin Cancer Res. 2006 Jan 15;12(2):447-53. doi: 10.1158/1078-0432.CCR-05-1477. Clin Cancer Res. 2006. PMID: 16428485

2

New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA.

Onda M, Willingham M, Nagata S, Bera TK, Beers R, Ho M, Hassan R, Kreitman RJ, Pastan I. Onda M, et al. Among authors: willingham m. Clin Cancer Res. 2005 Aug 15;11(16):5840-6. doi: 10.1158/1078-0432.CCR-05-0578. Clin Cancer Res. 2005. PMID: 16115924

3

Localization of mesothelin in epithelial ovarian cancer.

Hassan R, Kreitman RJ, Pastan I, Willingham MC. Hassan R, et al. Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):243-7. doi: 10.1097/01.pai.00000141545.36485.d6. Appl Immunohistochem Mol Morphol. 2005. PMID: 16082249

4

Mesothelin expression in human lung cancer.

Ho M, Bera TK, Willingham MC, Onda M, Hassan R, FitzGerald D, Pastan I. Ho M, et al. Among authors: willingham mc. Clin Cancer Res. 2007 Mar 1;13(5):1571-5. doi: 10.1158/1078-0432.CCR-06-2161. Clin Cancer Res. 2007. PMID: 17332303

5

Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.

Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, Pastan I. Hassan R, et al. Clin Cancer Res. 2007 Sep 1;13(17):5144-9. doi: 10.1158/1078-0432.CCR-07-0869. Clin Cancer Res. 2007. PMID: 17785569 Clinical Trial.

6

NGEP, a prostate-specific plasma membrane protein that promotes the association of LNCaP cells.

Das S, Hahn Y, Nagata S, Willingham MC, Bera TK, Lee B, Pastan I. Das S, et al. Cancer Res. 2007 Feb 15;67(4):1594-601. doi: 10.1158/0008-5472.CAN-06-2673. Cancer Res. 2007. PMID: 17308099

7

Topology of NGEP, a prostate-specific cell:cell junction protein widely expressed in many cancers of different grade level.

Das S, Hahn Y, Walker DA, Nagata S, Willingham MC, Peehl DM, Bera TK, Lee B, Pastan I. Das S, et al. Among authors: willingham mc. Cancer Res. 2008 Aug 1;68(15):6306-12. doi: 10.1158/0008-5472.CAN-08-0870. Cancer Res. 2008. PMID: 18676855 Free PMC article.

8

Frequent expression of the tumor antigen CAK1 in squamous-cell carcinomas.

Chang K, Pastan I, Willingham MC. Chang K, et al. Among authors: willingham mc. Int J Cancer. 1992 Jun 19;51(4):548-54. doi: 10.1002/ijc.2910510408. Int J Cancer. 1992. PMID: 1351045

9

Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium.

Chang K, Pai LH, Batra JK, Pastan I, Willingham MC. Chang K, et al. Among authors: willingham mc. Cancer Res. 1992 Jan 1;52(1):181-6. Cancer Res. 1992. PMID: 1727378

10

Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium.

Chang K, Pastan I, Willingham MC. Chang K, et al. Among authors: willingham mc. Int J Cancer. 1992 Feb 1;50(3):373-81. doi: 10.1002/ijc.2910500308. Int J Cancer. 1992. PMID: 1735605

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

453 results

Search Page

Filters